FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998796817> ?p ?o ?g. }

• W1998796817 endingPage "265" @default.
• W1998796817 startingPage "254" @default.
• W1998796817 abstract "This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization. This international, randomized, double-blind study included a 2-week monotherapy phase followed by a 4-week additive therapy phase. Recently exacerbated patients with schizophrenia or schizoaffective disorder (DSM-IV) were randomized (2:2:1) to risperidone (n = 153), quetiapine (n = 156), or placebo (n = 73). Target doses were 4 or 6 mg/day of risperidone and 400 or 600 mg/day of quetiapine by day 5, with the ability to increase to 600 or 800 mg/day of quetiapine on day 8. The main outcome measures were the total Positive and Negative Syndrome Scale (PANSS) and need for additional psychotropic medications. Monotherapy Phase: The combined atypical antipsychotic group (n = 308) reached borderline superiority to placebo (n = 71) at the 2-week endpoint on mean change in total PANSS score (− 24.1 ± 1.2 and − 20.2 ± 2.0, respectively; p = 0.067). The change in the atypical group was driven by the improvement with risperidone (− 27.7 ± 1.5 vs. − 20.2 ± 2.0 with placebo, p < 0.01; and vs. − 20.5 ± 1.5 with quetiapine, p < 0.01); the improvement with quetiapine was similar to placebo, p = 0.879. Results were similar on other efficacy endpoints. Additive Therapy Phase: Additional psychotropics were prescribed to fewer (p < 0.01) risperidone (36%) than quetiapine (53%) or placebo patients (59%). The overall discontinuation rate was 18%, 26%, and 38%, respectively. Risperidone, compared with placebo, was associated with more parkinsonism, akathisia, plasma prolactin changes, and weight gain; while quetiapine was associated with more somnolence, sedation, dizziness, constipation, tachycardia, thyroid dysregulation, and weight gain. While the combined atypical antipsychotic group did not experience greater improvements than the placebo group, risperidone, but not quetiapine, was significantly superior in all measured domains to placebo in the management of recently exacerbated hospitalized patients with schizophrenia or schizoaffective disorder, with no unexpected tolerability findings." @default.
• W1998796817 created "2016-06-24" @default.
• W1998796817 creator A5009946921 @default.
• W1998796817 creator A5011009026 @default.
• W1998796817 creator A5017994555 @default.
• W1998796817 creator A5024595502 @default.
• W1998796817 creator A5039370667 @default.
• W1998796817 creator A5042570301 @default.
• W1998796817 creator A5061822923 @default.
• W1998796817 creator A5063251263 @default.
• W1998796817 creator A5063293385 @default.
• W1998796817 creator A5076875466 @default.
• W1998796817 creator A5087959929 @default.
• W1998796817 date "2006-07-01" @default.
• W1998796817 modified "2023-10-01" @default.
• W1998796817 title "A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization" @default.
• W1998796817 cites W1556488229 @default.
• W1998796817 cites W1995051494 @default.
• W1998796817 cites W1999689270 @default.
• W1998796817 cites W2000636120 @default.
• W1998796817 cites W2006019396 @default.
• W1998796817 cites W2009915820 @default.
• W1998796817 cites W2015837785 @default.
• W1998796817 cites W2019879674 @default.
• W1998796817 cites W2041474698 @default.
• W1998796817 cites W2060802427 @default.
• W1998796817 cites W2067786055 @default.
• W1998796817 cites W2077138902 @default.
• W1998796817 cites W2081069399 @default.
• W1998796817 cites W2085360366 @default.
• W1998796817 cites W2102623411 @default.
• W1998796817 cites W2114613490 @default.
• W1998796817 cites W2119369900 @default.
• W1998796817 cites W2128825342 @default.
• W1998796817 cites W2140606211 @default.
• W1998796817 cites W2141441326 @default.
• W1998796817 cites W2159155203 @default.
• W1998796817 cites W2162993517 @default.
• W1998796817 cites W2165379748 @default.
• W1998796817 cites W2166945572 @default.
• W1998796817 cites W3090293687 @default.
• W1998796817 cites W3215125900 @default.
• W1998796817 cites W2245231029 @default.
• W1998796817 doi "https://doi.org/10.1016/j.schres.2006.03.027" @default.
• W1998796817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16797162" @default.
• W1998796817 hasPublicationYear "2006" @default.
• W1998796817 type Work @default.
• W1998796817 sameAs 1998796817 @default.
• W1998796817 citedByCount "79" @default.
• W1998796817 countsByYear W19987968172012 @default.
• W1998796817 countsByYear W19987968172013 @default.
• W1998796817 countsByYear W19987968172014 @default.
• W1998796817 countsByYear W19987968172015 @default.
• W1998796817 countsByYear W19987968172016 @default.
• W1998796817 countsByYear W19987968172017 @default.
• W1998796817 countsByYear W19987968172018 @default.
• W1998796817 countsByYear W19987968172019 @default.
• W1998796817 countsByYear W19987968172020 @default.
• W1998796817 countsByYear W19987968172021 @default.
• W1998796817 countsByYear W19987968172022 @default.
• W1998796817 countsByYear W19987968172023 @default.
• W1998796817 crossrefType "journal-article" @default.
• W1998796817 hasAuthorship W1998796817A5009946921 @default.
• W1998796817 hasAuthorship W1998796817A5011009026 @default.
• W1998796817 hasAuthorship W1998796817A5017994555 @default.
• W1998796817 hasAuthorship W1998796817A5024595502 @default.
• W1998796817 hasAuthorship W1998796817A5039370667 @default.
• W1998796817 hasAuthorship W1998796817A5042570301 @default.
• W1998796817 hasAuthorship W1998796817A5061822923 @default.
• W1998796817 hasAuthorship W1998796817A5063251263 @default.
• W1998796817 hasAuthorship W1998796817A5063293385 @default.
• W1998796817 hasAuthorship W1998796817A5076875466 @default.
• W1998796817 hasAuthorship W1998796817A5087959929 @default.
• W1998796817 hasConcept C118552586 @default.
• W1998796817 hasConcept C126322002 @default.
• W1998796817 hasConcept C142724271 @default.
• W1998796817 hasConcept C15744967 @default.
• W1998796817 hasConcept C204787440 @default.
• W1998796817 hasConcept C27081682 @default.
• W1998796817 hasConcept C2776412080 @default.
• W1998796817 hasConcept C2776921671 @default.
• W1998796817 hasConcept C2777014857 @default.
• W1998796817 hasConcept C2778715236 @default.
• W1998796817 hasConcept C2779727114 @default.
• W1998796817 hasConcept C2780057945 @default.
• W1998796817 hasConcept C2780135775 @default.
• W1998796817 hasConcept C2780325297 @default.
• W1998796817 hasConcept C2780494398 @default.
• W1998796817 hasConcept C2780634440 @default.
• W1998796817 hasConcept C2911140283 @default.
• W1998796817 hasConcept C71924100 @default.
• W1998796817 hasConcept C90924648 @default.
• W1998796817 hasConceptScore W1998796817C118552586 @default.
• W1998796817 hasConceptScore W1998796817C126322002 @default.
• W1998796817 hasConceptScore W1998796817C142724271 @default.
• W1998796817 hasConceptScore W1998796817C15744967 @default.
• W1998796817 hasConceptScore W1998796817C204787440 @default.
• W1998796817 hasConceptScore W1998796817C27081682 @default.

• next